Evotec

EVOPhase 2

Hamburg, GermanyFounded 1993evotec.com

Evotec is a technology-driven drug discovery and development powerhouse, offering a fully integrated R&D value chain from target identification to IND-enabling studies. Its business model combines standalone CRO services with integrated strategic partnerships and a co-owned portfolio of over 100 proprietary R&D assets. With a focus on scientific excellence and operational agility, Evotec aims to deliver unmatched speed and efficiency, ensuring better treatments reach patients sooner through its global team of over 4,800 experts.

Market Cap

$863.8M

Founded

1993

Employees

4,800-5,000

Focus

Drug DiscoveryAI / Machine LearningNeuroscience

EVO · Stock Price

USD 2.4311.99 (-83.15%)

Historical price data

AI Company Overview

Technology Platform

A fully integrated suite of proprietary platforms including Molecular Patient Databases, PanOmics, iPSC-based disease modeling, AI-driven data science, and the Just-Evotec Biologics platform for continuous manufacturing of biologics.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT)	Smoking Cessation	Phase 2
EVT 201	Sleep Initiation and Maintenance Disorders	Phase 2
EVT 302 + Placebo + EVT 302 plus open label Nicotine replacement + Placebo plus ...	Smoking Cessation	Phase 2
EVT 201	Sleep Initiation and Maintenance Disorders	Phase 2
EVT 101 + EVT 101 + placebo	Human Volunteers	Phase 1

Funding History

Total raised: $150M

PIPE$150MUndisclosedJun 15, 2021

IPOUndisclosedUndisclosedJun 15, 1999

Opportunities

Significant growth opportunities exist in expanding its Just-Evotec Biologics manufacturing platform, advancing its co-owned portfolio of over 100 assets into clinical stages, and deepening integrated partnerships with large pharma.

The increasing industry reliance on external innovation and complex modalities aligns perfectly with Evotec's core capabilities.

Risk Factors

Key risks include dependence on strategic partners, the inherent failure risk of drug development programs in its co-owned portfolio, intense competition in the CRO/CDMO sector pressuring margins, and execution risks associated with scaling novel technology platforms like continuous biologics manufacturing.

Competitive Landscape

Evotec competes with large CROs (e.g., LabCorp, IQVIA), specialist discovery firms (e.g., WuXi AppTec), and biologics CDMOs (e.g., Lonza). Its differentiation lies in its proprietary technology platforms, integrated partnership model with asset co-ownership, and deep scientific expertise in complex modalities and therapeutic areas.

Publications

Patents

Pipeline